Abstract: Provided are novel compounds having an inhibitory activity against production or secretion of ?-amyloid protein. They embrace compounds represented by the following formula (1): and capable of being replaced with a variety of substituents; and salts thereof, and solvates of any one of them.

Abstract: A liquid preparation having improved light stability is provided, which comprises an aqueous solution containing sitafloxacin and sodium chloride.

Abstract: The present invention provides an agent for inhibiting metastasis of colorectal cancer and a method for inhibiting metastasis of colorectal cancer, which inhibit the function of Asef (i.e., binding activity to the APC gene product or guanine nucleotide exchange factor activity) that binds to the gene product of the tumor suppressor gene APC that plays an important role in tumorigenesis and in developmental processes, and/or inhibit the expression of the Asef gene.

Abstract: The present invention was aimed at reducing transcription activating activity of MITF-M to inhibit production of BCL2 gene product and thereby to allow treatment and/or prevention of melanoma The present invention provided a method of inhibiting production of BCL2 gene product and an agent for inhibiting the same, which inhibit binding of protein selected from a group consisting of HLF, ELK4 and CLOCK to MITF-M, a method of inducing cell death of melanoma cells, an agent for inducing the same, an agent for treating and/or preventing diseases accompanied by enhanced production of BCL2 gene product, such as melanoma, a method of treating and/or preventing the diseases, a method of identifying any one of the following compounds: a compound that inhibits the aforementioned binding; a compound that inhibits production of BCL2 gene product; and a compound that increases sensitivity of melanoma to melanoma drugs, as well as a reagent kit.

Abstract: A compound represented by Formula (I): wherein Ar1 represents Formula (II): Ar2 represents a 5- or 6-membered aromatic heterocyclic group which may be substituted; and X represents Formula (III): a salt thereof, or a solvate of the compound or the salt. A potent platelet aggregation suppressant which does not inhibit COX-1 and COX-2 is provided.

Abstract: A platelet coagulation inhibitor which inhibits neither COX-1 nor COX-2 is provided.

Abstract: A pharmaceutical composition containing a drug (A), a waxy substance (B), and synthetic aluminum silicate and/or hydrous silicon dioxide (C). The invention provides a granular pharmaceutical composition suitable for providing a pharmaceutical characterized in that adhesion of granules thereof onto a granulation apparatus during granulation is minimized and caking of the granules is suppressed.

Abstract: It is an object of the invention to provide a crosslinkable pressure-sensitive adhesive for skin that exhibits satisfactory adhesion and releasability for human skin and low irritation to skin, and a crosslinkable pressure-sensitive adhesive sheet for skin that is suitable for medical and cosmetic use, as well as to provide a composition for production of a crosslinkable pressure-sensitive adhesive for skin that has superior storage properties and is suitable for preparation of the crosslinkable pressure-sensitive adhesive for skin. The crosslinkable pressure-sensitive adhesive for skin of the invention is formed by 100 parts by weight of an acrylic copolymer (copolymer A) comprising a (meth) acrylic acid alkyl ester as the main constituent component and 3-45 wt % diacetoneacrylamide as an essential constituent component, and containing no free carboxyl groups, and 0.

Abstract: A method of industrially advantageously producing a cyclopropane monoacetal derivative represented by the formula (III) conveniently and also in a fewer steps by reacting a halogenated unsaturated carbonyl compound represented by the formula (II) with an alcoholate. wherein each symbol is as defined in the specification.

Abstract: Provided is an industrially applicable process for producing 1,2-cis-2-fluorocyclopropane-1-carboxylic ester.

Abstract: A novel protein and a process of producing the protein is provided. The protein is a glycoprotein having activity of suppressing the differentiation and/or maturation of adipocyte, having a molecular weight of about 45 kD under non-reducing conditions and about 28 kD and/or 23 kD under reducing conditions, and exhibiting affinity to heparin. A process of producing the protein comprising culturing human fibroblasts and purifying the culture broth by chromatography using an ion exchange column, affinity column, and reverse phase column. A cDNA encoding the protein and a process of producing the protein using the cDNA are also provided. The protein of the present invention is useful as a pharmaceutical composition for preventing or treating obesity or as an antigen for establishing immunological diagnosis, etc.

Abstract: Provision of a method for accurate diagnosis of mucopolysaccharidoses, including determining the level of glycosaminoglycan in a biological sample with high sensitivity and with ease.

Abstract: The present invention provides a tulobuterol adhesive patch comprising (a) a support, (b) an acrylic pressure-sensitive adhesive layer containing the percutaneously absorbing drug tulobuterol and if necessary a lipophilic oily plasticizer, and (c) a release liner, laminated in that order, wherein the acrylic pressure-sensitive adhesive is a copolymer obtained by copolymerizing an acrylic monomer which is acetoacetoxyalkyl (meth)acrylate with one or more other vinyl monomers, to yield a tulobuterol adhesive patch with excellent release and skin permeability of tulobuterol from the pressure-sensitive adhesive layer, low skin irritation and excellent safety.

Abstract: The present invention provides an advantageous process for producing an intermediate which is useful for producing a compound which exhibits excellent VLA-4 inhibitory effect and safety. Intermediates (III) and (XIII) are produced through conversion through the following reaction schemes.

Abstract: The present invention relates to a granular pharmaceutical composition comprising a drug having a disagreeable taste, a wax and a sugar alcohol; a method for preparing the same; and a pharmaceutical product for oral administration, comprising the granular composition. The product excellently masks a disagreeable taste possessed by a drug and provides good sensation upon oral administration, and therefore is easily ingested by even the elderly, children, and patients suffering dysphagia. Moreover, the product is suitable for administration using tube.

Abstract: The present invention provides processes for producing a compound (5) based on the following reaction scheme.

Abstract: A compound represented by the following formula (1): Q1—Q2—To—N(R1)—Q3—N(R2)—T1—Q4??(1) [wherein, R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may have a substituent, or the like; Q2 is a single bond or the like; Q3 represents the following group: —C(R3a)(R4a)—{C(R3b)(R4b)}m1—{C(R3c)(R4c)}m2—{C(R3d)(R4d)}m3—{C(R3e)(R4e)}m4—C (R3f)(R4f)— (in which, R3a to R4e represent hydrogen or the like); T0 represents a carbonyl group or the like; and T1 represents —COCONR— or the like]; or salt thereof, solvate thereof, or N-oxide thereof.

Abstract: It is an object of the present invention to find a protein interacting with Granzyme B and to provide a means for preventing and/or treating diseases caused by the decomposition of the above protein by Granzyme B. The present invention provides a method of using Golgin-160 as a substrate of Granzyme B; a method for screening an inhibitor of the interaction of Granzyme B with Golgin-160 and/or an inhibitor of the decomposition of Golgin-160 by Granzyme B; various types of agent which comprise an inhibitor of the interaction of Granzyme B with Golgin-160 and/or an inhibitor of the decomposition of Golgin-160 by Granzyme B; and a method for preventing and/or treating various diseases which comprises a step of inhibiting the interaction of Granzyme B with Golgin-160 and/or the decomposition of Golgin-160 by Granzyme B.

Abstract: A lipid membrane structure containing an anti-membrane-type matrix metalloproteinase monoclonal antibody such as an anti-MT1-MMP monoclonal antibody as a component of the lipid membrane structure. Said structure can be utilized as a drug delivery system for efficiently delivering a medicinally active ingredient and/or a gene to tumor cells, neoplastic vessel and the like in which a membrane-type matrix metalloproteinase (MT-MMP) is expressed.

Abstract: A method and an agent for inhibiting the oligomerization of procaspase-1, a method and an agent for inhibiting the activation of procaspase-1, a method and an agent for inhibiting the production of caspase-1, a method of preventing and/or treating an inflammatory disease, and an agent for preventing and/or treating an inflammatory disease, all of which comprise inhibiting the binding of NOD2 to procaspase-1; a method of identifying a compound that inhibits the binding of NOD2 to procaspase-1; and a reagent kit for use in the identifying method are provided.